FDA Approves AstraZeneca's Lynparza for Pancreatic Cancer

   By Sabela Ojea

AstraZeneca PLC (AZN.LN) said Monday that its pancreatic-cancer drug Lynparza has been approved by the U.S. Food and Drug Administration as a first-line maintenance treatment for metastatic pancreatic cancer.

The British drug maker said the drug has reduced the risk of disease progression or death by 47% in adult patients whose disease has not advanced on at least 16 weeks, as the results from the pivotal Phase 3 POLO trial showed.

The London-listed company said Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer.

"Metastatic pancreatic cancer patients have been waiting a long time for new therapy options for their devastating disease. Today's approval of Lynparza provides an exciting new treatment option for patients," Julie Fleshman, President and CEO of Pancreatic Cancer Action Network, said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

December 30, 2019 02:27 ET (07:27 GMT)

AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024